American Society of Hirudotherapy

Bivalent direct thrombin inhibitors: hirudin and bivalirudin

Research article published in Best practice & research. Clinical haematology (2004)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentWarkentin T · Best practice & research. Clinical haematology, 2004

Abstract

Hirudin derivatives (e.g. lepirudin, desirudin) and hirudin analogues (e.g. bivalirudin) are bivalent direct thrombin inhibitors; that is, they bind to two distinct sites on thrombin-its active (catalytic) site and its fibrinogen-binding site (exosite 1). These bivalent binding properties contribute to their high affinity and high specificity for thrombin. This review compares the pharmacological properties of these agents, and describes studies of their efficacy and safety in diverse clinical settings such as immune heparin-induced thrombocytopenia, postoperative antithrombotic prophylaxis, and treatment of acute coronary syndrome. Certain disadvantages of hirudin, such as its predominant renal excretion and immunogenicity, have been overcome through development of the hirudin analogue, bivalirudin. Compared with hirudin derivatives, bivalirudin exhibits a shorter half-life (25 vs 80 minutes), predominant non-renal (enzymic) metabolism, and low immunogenicity. Further work is required to define the scope of clinical thrombosis problems that could benefit from these novel agents.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsAntithrombinsBinding SitesHirudin TherapyHirudinsHumansPeptide FragmentsRecombinant ProteinsTreatment Outcome

Summary

Hirudin derivatives (e. g.

Why This Matters for Hirudotherapy

This review compares the pharmacological properties, clinical efficacy, and safety of hirudin derivatives (lepirudin, desirudin) and the hirudin analogue bivalirudin—both bivalent direct thrombin inhibitors that bind thrombin's active catalytic site and fibrinogen-binding exosite 1—across settings including heparin-induced thrombocytopenia, postoperative antithrombotic prophylaxis, and acute coronary syndrome. Because hirudin-family compounds are the anticoagulant class lending its name to hirudotherapy, the detailed pharmacological comparisons here—including bivalirudin's advantages of shorter half-life (25 vs 80 minutes), enzymatic non-renal metabolism, and lower immunogenicity over hirudin—are of conceptual interest to ASH's domain. However, the abstract addresses only pharmaceutical derivatives and analogues; it does not mention leeches, leech saliva, the salivary secretome, or live leech therapy. As a review, this article synthesizes existing evidence without new primary data, and its connection to actual hirudotherapy is indirect.

Citation

Bivalent direct thrombin inhibitors: hirudin and bivalirudin.

Warkentin T · Best practice & research. Clinical haematology, 2004

DOI

Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.